Wilson Sonsini Goodrich & Rosati advised Ji Xing Pharmaceuticals Limited (JIXING) on the transaction. TMS Co., Ltd. (TMS) and Ji Xing Pharmaceuticals Limited (JIXING) announced that...
JIXING’s Collaborations with TMS
Arcellx’s Expansion of Partnership with Kite
Wilson Sonsini Goodrich & Rosati is advising Arcellx on the transaction. Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD) announced that they have...
LENZ Therapeutics’ Merger with Graphite Bio
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
JURA Bio’s $16.1 Million Financing and Replay Collaboration
Wilson Sonsini Goodrich & Rosati advised JURA Bio on both the financing transaction and the collaboration agreement. JURA Bio announced a research collaboration with Syena, a cell...
Oricell Therapeutics’ $45 Million Series B1 Financing
Wilson Sonsini Goodrich & Rosati advised RTW Investments on the deal. Oricell Therapeutics Co., Ltd, a China-based innovative pharmaceutical company committed to the development of tumor...
Pearl Health’s $75 Million Series B
Wilson Sonsini advised a16z on the deal. Pearl Health, a leading technology company focused on physician enablement and risk bearing in value-based care, announced it has...
Arcellx’s $4 Billion Collaboration with Kite
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...
ATP’s Launch of Ascidian Therapeutics
Wilson Sonsini Goodrich & Rosati advised Ascidian Therapeutics on the deal. Life sciences venture capital firm ATP announced the launch of new biotechnology company Ascidian Therapeutics....
Rivus Pharmaceuticals’ $132 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised RA Capital Management on the deal. Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion...
Faeth Therapeutics’ $47 Million Series A Financing
Wilson Sonsini advised Faeth Therapeutics on the deal. Faeth Therapeutics, a cancer metabolism company, announced the completion of a Series A financing of $47 million led...
Arcellx’s $112 Million Public Offering
Wilson Sonsini advised Arcellx on the deal. Arcellx, a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other...
Cellino’s $80 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Cellino on the deal. Cellino Biotech, an autonomous cell therapy manufacturing company, announced the completion of a Series A financing...